1. 2023 International Consensus Meeting on Musculoskeletal Infection: Summary from the Treatment Workgroup and Consensus on Treatment in Preclinical Models
- Author
-
Amber Jennings, J, Arts, Chris, Falconer, Robert, Ashton, Nicholas, Williams, Dustin, Duffy, Hannah, Hamilton, John, Markovics, Adrienn, Gianotti, Sofia, Tate, Jermiah, Montgomery, Emily C, Abuhussein, Ezzuddin, Dintakurthi, Yogita, Ren, Youliang, Weeks, Jason, Xie, Chao, Ricciardi, Benjamin, van Hoogstraten, Sanne, Mdingi, Vuyisa, Vanvelk, Niels, Hylen, Annika, Baertl, Susanne, Alt, Volker, Morgenstern, Mario, Priddy, Lauren B, Tucker, Luke J, Gautreaux, Malley A, Ducheyne, Paul, Bhattacharyya, Sanjib, Obremskey, William T, Libos, Andres, Cain, Jarrett D, Hickok, Noreen J, Schwarz, Edward M, Fintan Moriarty, T, Amber Jennings, J, Arts, Chris, Falconer, Robert, Ashton, Nicholas, Williams, Dustin, Duffy, Hannah, Hamilton, John, Markovics, Adrienn, Gianotti, Sofia, Tate, Jermiah, Montgomery, Emily C, Abuhussein, Ezzuddin, Dintakurthi, Yogita, Ren, Youliang, Weeks, Jason, Xie, Chao, Ricciardi, Benjamin, van Hoogstraten, Sanne, Mdingi, Vuyisa, Vanvelk, Niels, Hylen, Annika, Baertl, Susanne, Alt, Volker, Morgenstern, Mario, Priddy, Lauren B, Tucker, Luke J, Gautreaux, Malley A, Ducheyne, Paul, Bhattacharyya, Sanjib, Obremskey, William T, Libos, Andres, Cain, Jarrett D, Hickok, Noreen J, Schwarz, Edward M, and Fintan Moriarty, T
- Abstract
In vitro and in vivo studies are critical for the preclinical efficacy assessment of novel therapies targeting musculoskeletal infections (MSKI). Many preclinical models have been developed and applied as a prelude to evaluating safety and efficacy in human clinical trials. In performing these studies, there is both a requirement for a robust assessment of efficacy, as well as a parallel responsibility to consider the burden on experimental animals used in such studies. Since MSKI is a broad term encompassing infections varying in pathogen, anatomical location and implants used, there are also a wide range of animal models described modelling these disparate infections. Although some of these variations are required to adequately evaluate specific interventions, there would be enormous value in creating a unified and standardized criteria to animal testing in the treatment of MSKI. The Treatment Workgroup of the 2023 International Consensus Meeting on Musculoskeletal Infection was responsible for questions related to preclinical models for treatment of MSKI. The main objective was to review the literature related to priority questions and estimate consensus opinion after voting. This document presents that process and results for preclinical models related to 1) animal model considerations, 2) outcome measurements, and 3) imaging. This article is protected by copyright. All rights reserved.
- Published
- 2024